RecruitingNot ApplicableNCT06430346
Exercise Prehabilitation for Locoregional Esophageal Cancer
Exercise Prehabilitation for Locoregional Esophageal Cancer: A Pilot Study
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Enrollment
20 participants
Start Date
May 21, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to examine the feasibility and acceptability of exercise "prehabilitation" for patients preparing for esophageal cancer resection (removal).
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Biopsy-proven locoregional esophageal cancer (LEC)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Treatment plan including neoadjuvant chemoradiation therapy and surgical resection
- Ability to read and speak English
Exclusion Criteria6
- Regular engagement in resistance training (2x/week targeting all major muscle groups)
- Screen failure for exercise safety based on PAR-Q
- Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease
- Recent fracture or acute musculoskeletal injury that precludes ability to participate in resistance training safely
- Numeric pain rating scale of 7 or more out of 10
- Myopathic or rheumatologic disease that impacts physical function
Interventions
BEHAVIORALExercise
Physical activity and resistance training
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06430346
Related Trials
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT0721770410 locations
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT0644597243 locations
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT0646994443 locations